Company Name: |
Daicel Chiral Technologies (China)CO.,LTD
|
Tel: |
021-50460086-9 15921403865 |
Email: |
han_yajun@dctc.daicel.com |
Products Intro: |
Product Name:9-[[2-(2,6-Dioxo-3-piperidyl)-1,3-dioxoisoindolin-4-yl]amino]nonanoic Acid CAS:2305936-70-1 Purity:95% Package:250mg;1g Remarks:209665
|
Company Name: |
Chengdu Novel Biomedical Co., Ltd.
|
Tel: |
028-85255396 18302801538 |
Email: |
cdnovell@163.com |
Products Intro: |
Product Name:Nonanoic acid, 9-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- CAS:2305936-70-1 Purity:98%+ Package:5g;10g
|
Nonanoic acid, 9-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- manufacturers
|
| Nonanoic acid, 9-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- Basic information |
Product Name: | Nonanoic acid, 9-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- | Synonyms: | Nonanoic acid, 9-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-;OUN 36701;9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)nonanoic acid;Thalidomide-4-NH-C8-COOH;9-[[2-(2,6-Dioxo-3-piperidyl)-1,3-dioxoisoindolin-4-yl]amino]nonanoic Acid;Poma-C?-COOH;Pomalidomide 4'-alkylC8-acid;9-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}nonanoic acid | CAS: | 2305936-70-1 | MF: | C22H27N3O6 | MW: | 429.47 | EINECS: | | Product Categories: | | Mol File: | 2305936-70-1.mol | |
| Nonanoic acid, 9-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- Chemical Properties |
Boiling point | 718.9±60.0 °C(Predicted) | density | 1.351±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | pka | 4.78±0.10(Predicted) |
| Nonanoic acid, 9-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- Usage And Synthesis |
Description | Pomalidomide C8-acid, also known as Pomalidomide 4'-alkylC8-acid and OUN36701, is a Pomalidomide-based cereblon ligand with a linker, which is a useful precursor for synthesis of PROTAC degraders. Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional small molecules. PROTAC degraders are usually heterobifunctional small molecules consisting of two ligands joined by a linker: one ligand recruits and binds a protein of interest (POI) while the other recruits and binds an E3 ubiquitin ligase. Simultaneous binding of the POI and ligase by the PROTAC induces ubiquitylation of the POI and its subsequent degradation by the ubiquitin–proteasome system (UPS), after which the PROTAC is recycled to target another copy of the POI.ubiquitylation of the POI and its subsequent degradation by the ubiquitin–proteasome system (UPS), after which the PROTAC is recycled to target another copy of the POI. | storage | Store at -20°C |
| Nonanoic acid, 9-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- Preparation Products And Raw materials |
|